Organ Preservation Firm Bridge to Life Raises $110M

Bridge to Life, a significant player in the organ preservation and perfusion technology sector, has successfully closed a substantial $110 million funding round. This financing comprises both Series C equity and debt, signaling strong investor confidence in the company's commercial trajectory and future product development.

The equity portion of the raise was spearheaded by new entrant Soleus Capital, with active participation from Lauxera Capital Partners. Notably, the company's own directors, officers, and employees also contributed, underscoring internal belief in the organization's mission. Complementing the equity, Soleus Capital Credit Opportunities Fund provided the debt financing, a move that also facilitated the refinancing of existing credit facilities with Perceptive Credit Funds. This strategic debt restructuring significantly reduces Bridge to Life's leverage and lowers its overall interest expense.

Funds from this significant capital infusion are earmarked for several key strategic initiatives. A primary objective is the aggressive rollout of the company's VitaSmart™ platform. This involves expanding the sales and support field team to ensure comprehensive reach across all U.S. transplant centers. The capital will also provide the necessary working capital to support this market penetration.

Beyond the immediate launch of VitaSmart™, a portion of the proceeds will be dedicated to advancing Bridge to Life's innovation pipeline. This includes the development of a proprietary organ viability assessment tool, which promises to enhance the existing organ preservation portfolio. Furthermore, the company plans to leverage these funds to scale its international operations, reflecting a global ambition in addressing the critical need for effective organ preservation solutions.

The organ preservation market is experiencing heightened attention, driven by increasing organ transplant demand and advancements in medical technology. Innovations like those from Bridge to Life are crucial in improving transplant success rates and expanding the donor organ pool. The company's focus on perfusion technologies, which maintain organs in a more physiological state outside the body compared to traditional static cold storage, positions it at the forefront of this evolving field. This $110 million injection is expected to accelerate its competitive positioning within this vital healthcare segment.

This funding round marks a pivotal moment for Bridge to Life, transitioning it from an early-stage development entity to a fully commercialized organization with ambitious growth plans. The successful closure, particularly with the involvement of specialized credit funds and new equity partners, highlights the increasing investor appetite for medtech solutions that address critical unmet needs in patient care and healthcare efficiency.